Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report)’s share price rose 4.4% during mid-day trading on Thursday. The stock traded as high as $14.71 and last traded at $14.3810. 552,901 shares changed hands during trading, a decline of 59% from the average daily volume of 1,350,053 shares. The stock had previously closed at $13.78.
Analyst Ratings Changes
A number of research analysts have recently weighed in on the company. Wall Street Zen downgraded Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. UBS Group initiated coverage on Mineralys Therapeutics in a report on Sunday, October 11th. They set a “neutral” rating and a $29.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Thursday, October 15th. Zacks Research upgraded Mineralys Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, September 11th. Finally, HC Wainwright reissued a “buy” rating and set a $56.00 target price on shares of Mineralys Therapeutics in a research note on Monday, October 12th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $43.60.
Get Our Latest Research Report on MLYS
Mineralys Therapeutics Trading Down 3.5%
The business’s 50-day moving average price is $21.12 and its 200 day moving average price is $25.75. The company has a debt-to-equity ratio of 0.15, a quick ratio of 11.83 and a current ratio of 11.83. The company has a market cap of $1.21 billion, a P/E ratio of -3.13 and a beta of 0.83.
Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.09). As a group, analysts expect that Mineralys Therapeutics, Inc. will post -4.64 earnings per share for the current year.
Insider Transactions at Mineralys Therapeutics
In other news, CEO Jon Congleton sold 75,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $25.46, for a total value of $1,909,500.00. Following the completion of the transaction, the chief executive officer directly owned 528,621 shares of the company’s stock, valued at $13,458,690.66. This represents a 12.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daphne Karydas sold 3,000 shares of Mineralys Therapeutics stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $28.58, for a total value of $85,740.00. Following the sale, the director owned 6,200 shares in the company, valued at $177,196. This trade represents a 32.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 189,758 shares of company stock worth $5,209,856. Insiders own 18.94% of the company’s stock.
Hedge Funds Weigh In On Mineralys Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in shares of Mineralys Therapeutics during the second quarter valued at approximately $158,832,000. Orbimed Advisors LLC lifted its position in Mineralys Therapeutics by 109.4% during the first quarter. Orbimed Advisors LLC now owns 2,052,900 shares of the company’s stock valued at $55,613,000 after buying an additional 1,072,500 shares during the period. Bank of America Corp DE purchased a new position in Mineralys Therapeutics during the second quarter valued at $40,620,000. American Century Companies Inc. boosted its holdings in shares of Mineralys Therapeutics by 22.7% during the 3rd quarter. American Century Companies Inc. now owns 1,272,064 shares of the company’s stock valued at $31,967,000 after buying an additional 235,297 shares in the last quarter. Finally, Aberdeen Group plc boosted its holdings in shares of Mineralys Therapeutics by 29.8% during the 3rd quarter. Aberdeen Group plc now owns 894,403 shares of the company’s stock valued at $22,476,000 after buying an additional 205,168 shares in the last quarter. 84.46% of the stock is currently owned by hedge funds and other institutional investors.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing treatments for hypertension and other cardiovascular and kidney conditions associated with excess aldosterone. The company is based in Radnor, Pennsylvania, and was founded in 2019. Its lead product candidate, lorundrostat, is an investigational oral inhibitor of aldosterone synthase. Mineralys is studying the drug as a potential treatment for difficult-to-control hypertension and conditions related to excess aldosterone; it is not an approved or marketed therapy.
See Also
- Five stocks we like better than Mineralys Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
